The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: Analyses from a randomized, placebo-controlled trial

Pediatric Rheumatology

Volumn 8, Issue , 2010, Pages

  Visvanathan, Sudha ^a,b   Wagner, Carrie ^b   Marini, Joseph C ^b   Lovell, Daniel J ^c   Martini, Alberto ^d   Petty, Ross ^e   Cuttica, Ruben ^f   Woo, Patricia ^g   Espada, Graciela ^h   Gattorno, Marco ^d   Apaz, Maria T ⁱ   Baildam, Eileen ^j   Fasth, Anders ^k   Gerloni, Valeria ^l   Lahdenne, Pekka ^m   Quartier, Pierre ⁿ   Saurenmann, Rotraud ^o   Travers, Suzanne ^b   Mendelsohn, Alan ^b   Xu, Stephen ^b   Giannini, Edward H ^c   Ruperto, Nicolino ^d   more..

^a HOFFMANN LA ROCHE INC   (United States)

^b CENTOCOR INC   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

ⁱ UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

^j ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^k QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^l ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^m HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁿ HÔPITAL NECKER ENFANTS MALADES   (France)

^o UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P40; INTERLEUKIN 6; METHOTREXATE; PLACEBO; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADOLESCENT; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; HUMAN; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT RESPONSE;

EID: 77957338131     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-8-24     Document Type: Article

References (17)

1. Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993: is the epidemiology changing?. Arthritis Rheum 1996, 39:1385-1390. 10.1002/art.1780390817, 8702448.
2. Rosenberg AM. Analysis of a pediatric rheumatology clinic population. J Rheumatol 1990, 17:827-830.
3. Moore TL. Immunopathogenesis of juvenile rheumatoid arthritis. Curr Opin Rheumatol 1999, 11:377-383. 10.1097/00002281-199909000-00009, 10503658.
4. De Benedetti F, Robbioni P, Massa M, Viola S, Albani S, Martini A. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol 1992, 10:493-498.
5. Maeno N, Takei S, Imanaka H, Takasaki I, Kitajima I, Maruyama I, Matsuo K, Miyata K. Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis. J Rheumatol 1999, 26:2244-2248.
6. Gattorno M, Vignola S, Falcini F, Sabatini F, Buoncompagni A, Simonini G, Picco P, Pistoia V. Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002, 29:826-831.
7. Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008, 35:515-519.
8. Dolezalová P, Telelesová P, Nemcová D, Hoza J. Soluble adhesion molecules ICAM-1 and E-selectin in juvenile arthritis: clinical and laboratory correlations. Clin Exp Rheumatol 2002, 20:249-254.
9. Visvanathan S, Marini JC, Smolen JS, St Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Han J, Wagner C. Changes in Biomarkers of Inflammation and Bone Turnover and Associations with Clinical Efficacy Following Infliximab plus Methotrexate Therapy in Patients with Early Rheumatoid Arthritis. J Rheumatol 2007, 34:1465-1474.
10. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369:767-778. 10.1016/S0140-6736(07)60363-8, 17336654.
11. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SKF, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesley R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A, . for the Pediatric Rheumatology International Trials Organization A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004, 50:2191-2201. 10.1002/art.20288, 15248217, for the Pediatric Rheumatology International Trials Organization.
12. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK, . for the Pediatric Rheumatology Collaborative Study Group Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769. 10.1056/NEJM200003163421103, 10717011, for the Pediatric Rheumatology Collaborative Study Group.
13. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A, , . Pediatric Rheumatology Collaborative Study Group, Peadiatric Rheumatology International Trials Organisation Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359:810-820. 10.1056/NEJMoa0706290, 18716298, Pediatric Rheumatology Collaborative Study Group, Peadiatric Rheumatology International Trials Organisation.
14. Levalampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007, 36:189-193. 10.1080/03009740601089234, 17657672.
15. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balough Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szaer I, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychavdhuri A, Mendelsohn A, Martini A, Giannini EH, , . the Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007, 56:3096-3106. 10.1002/art.22838, 17763439, the Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group.
16. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997, 40:1202-1209.
17. Scola MP, Thomson SD, Brunner HI, Tsoras MK, Witte D, van Dijk MA, Grom AA, Passo MH, Glass DN. Interferon-γ: Interleukin 4 ratios and associated type 1 cytokine expression in juvenile rheumatoid arthritis synovial tissue. J Rheumatol 2002, 29:;369-378.